Cargando…

The evaluation of IgG4 and IgG expression in cutaneous Rosai-Dorfman disease()

OBJECTIVE: The authors investigated the expression of IgG4 and IgG in cutaneous Rosai-Dorfman Disease (CRDD) to further improve the understanding of this disease. METHODS: The authors retrospectively reviewed the clinicopathological features of 23 CRDD patients. The authors diagnosed CRDD by the pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Puyu, Zhan, Yi, Xue, Ruzeng, Liu, Yu, Zhang, Guiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404508/
https://www.ncbi.nlm.nih.gov/pubmed/37301673
http://dx.doi.org/10.1016/j.abd.2022.07.010
_version_ 1785085313506344960
author Zou, Puyu
Zhan, Yi
Xue, Ruzeng
Liu, Yu
Zhang, Guiying
author_facet Zou, Puyu
Zhan, Yi
Xue, Ruzeng
Liu, Yu
Zhang, Guiying
author_sort Zou, Puyu
collection PubMed
description OBJECTIVE: The authors investigated the expression of IgG4 and IgG in cutaneous Rosai-Dorfman Disease (CRDD) to further improve the understanding of this disease. METHODS: The authors retrospectively reviewed the clinicopathological features of 23 CRDD patients. The authors diagnosed CRDD by the presence of emperipolesis and immunohistochemical (IHC) staining of histiocytes consisting of S-100(+)/CD68(+)/CD1a(-) cells. The expressions of IgG and IgG4 in cutaneous specimens were assessed by IHC (EnVision) and quantitatively calculated by a medical image analysis system. RESULTS: All 23 patients, including 14 males and 9 females, were confirmed to have CRDD. Their ages ranged from 17 to 68 years (mean 47.91 ± 14.16). The most frequently affected skin regions were the face, followed by the trunk, ears, neck, limbs, and genitals. In 16 of these cases, the disease presented as a single lesion. IHC staining of sections showed that IgG was positive (≥ 10 cells/High-Power Field [HPF]) in 22 cases, while IgG4 was positive (≥ 10 cells/HPF) in 18 cases. Moreover, the IgG4/IgG proportion ranged from 1.7% to 85.7% (mean 29.50 ± 24.67%, median 18.4%) in the 18 cases. STUDY LIMITATIONS: In the majority of studies, as well as in the current study, the design. RDD is a rare disease, so the sample size is small. In the next studies to come, the authors will expand the sample for multi-center verification and in-depth study. CONCLUSION: The positive rates of IgG4 and IgG and the IgG4/IgG ratio assessed through IHC staining may be important in understanding the pathogenesis of CRDD.
format Online
Article
Text
id pubmed-10404508
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Sociedade Brasileira de Dermatologia
record_format MEDLINE/PubMed
spelling pubmed-104045082023-08-08 The evaluation of IgG4 and IgG expression in cutaneous Rosai-Dorfman disease() Zou, Puyu Zhan, Yi Xue, Ruzeng Liu, Yu Zhang, Guiying An Bras Dermatol Original Article OBJECTIVE: The authors investigated the expression of IgG4 and IgG in cutaneous Rosai-Dorfman Disease (CRDD) to further improve the understanding of this disease. METHODS: The authors retrospectively reviewed the clinicopathological features of 23 CRDD patients. The authors diagnosed CRDD by the presence of emperipolesis and immunohistochemical (IHC) staining of histiocytes consisting of S-100(+)/CD68(+)/CD1a(-) cells. The expressions of IgG and IgG4 in cutaneous specimens were assessed by IHC (EnVision) and quantitatively calculated by a medical image analysis system. RESULTS: All 23 patients, including 14 males and 9 females, were confirmed to have CRDD. Their ages ranged from 17 to 68 years (mean 47.91 ± 14.16). The most frequently affected skin regions were the face, followed by the trunk, ears, neck, limbs, and genitals. In 16 of these cases, the disease presented as a single lesion. IHC staining of sections showed that IgG was positive (≥ 10 cells/High-Power Field [HPF]) in 22 cases, while IgG4 was positive (≥ 10 cells/HPF) in 18 cases. Moreover, the IgG4/IgG proportion ranged from 1.7% to 85.7% (mean 29.50 ± 24.67%, median 18.4%) in the 18 cases. STUDY LIMITATIONS: In the majority of studies, as well as in the current study, the design. RDD is a rare disease, so the sample size is small. In the next studies to come, the authors will expand the sample for multi-center verification and in-depth study. CONCLUSION: The positive rates of IgG4 and IgG and the IgG4/IgG ratio assessed through IHC staining may be important in understanding the pathogenesis of CRDD. Sociedade Brasileira de Dermatologia 2023 2023-06-08 /pmc/articles/PMC10404508/ /pubmed/37301673 http://dx.doi.org/10.1016/j.abd.2022.07.010 Text en © 2023 Published by Elsevier España, S.L.U. on behalf of Sociedade Brasileira de Dermatologia. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Zou, Puyu
Zhan, Yi
Xue, Ruzeng
Liu, Yu
Zhang, Guiying
The evaluation of IgG4 and IgG expression in cutaneous Rosai-Dorfman disease()
title The evaluation of IgG4 and IgG expression in cutaneous Rosai-Dorfman disease()
title_full The evaluation of IgG4 and IgG expression in cutaneous Rosai-Dorfman disease()
title_fullStr The evaluation of IgG4 and IgG expression in cutaneous Rosai-Dorfman disease()
title_full_unstemmed The evaluation of IgG4 and IgG expression in cutaneous Rosai-Dorfman disease()
title_short The evaluation of IgG4 and IgG expression in cutaneous Rosai-Dorfman disease()
title_sort evaluation of igg4 and igg expression in cutaneous rosai-dorfman disease()
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404508/
https://www.ncbi.nlm.nih.gov/pubmed/37301673
http://dx.doi.org/10.1016/j.abd.2022.07.010
work_keys_str_mv AT zoupuyu theevaluationofigg4andiggexpressionincutaneousrosaidorfmandisease
AT zhanyi theevaluationofigg4andiggexpressionincutaneousrosaidorfmandisease
AT xueruzeng theevaluationofigg4andiggexpressionincutaneousrosaidorfmandisease
AT liuyu theevaluationofigg4andiggexpressionincutaneousrosaidorfmandisease
AT zhangguiying theevaluationofigg4andiggexpressionincutaneousrosaidorfmandisease
AT zoupuyu evaluationofigg4andiggexpressionincutaneousrosaidorfmandisease
AT zhanyi evaluationofigg4andiggexpressionincutaneousrosaidorfmandisease
AT xueruzeng evaluationofigg4andiggexpressionincutaneousrosaidorfmandisease
AT liuyu evaluationofigg4andiggexpressionincutaneousrosaidorfmandisease
AT zhangguiying evaluationofigg4andiggexpressionincutaneousrosaidorfmandisease